In a report released today, David Windley from Jefferies maintained a Hold rating on UnitedHealth (UNH – Research Report), with a price target of $500.00. The company’s shares closed yesterday at $441.72.
Windley covers the Healthcare sector, focusing on stocks such as Centene, Icon, and West Pharmaceutical Services. According to TipRanks, Windley has an average return of 12.9% and a 65.47% success rate on recommended stocks.
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $571.67, representing a 29.42% upside. In a report released on April 4, HSBC also upgraded the stock to a Hold with a $460.00 price target.
UNH market cap is currently $407.2B and has a P/E ratio of 18.51.
Based on the recent corporate insider activity of 146 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UNH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UnitedHealth (UNH) Company Description:
UnitedHealth Group, Inc. is a diversified healthcare company, offering healthcare coverage and benefits services through UnitedHealthcare, and information and technology-enabled health services through Optum. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minneapolis, MN.
Read More on UNH:
- Insiders Sold UnitedHealth (NYSE:UNH) Shares Before DoJ Probe Became Public
- UnitedHealth price target lowered to $546 from $607 at TD Cowen
- UnitedHealth price target lowered to $534 from $551 at Barclays
- UnitedHealth price target lowered to $584 from $618 at Morgan Stanley
- UnitedHealth Group (NYSE:UNH) Slides despite Analyst Upgrade
